Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

desmoteplase

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

- PMLiVE

MHRA launches second phase of genetic biobank for stroke prevention medicines

The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban

- PMLiVE

NICE recommends two AI-powered software tools for stroke diagnosis in NHS

Brainomix's e-Stroke and Ischemaview’s RapidAI were reported by the health technology assessment agency to improve access to treatment for stroke patients

- PMLiVE

NICE recommends wider use of statins to cut risk of heart attack and stroke

The guidance comes after new evidence was considered on the side effects and safety of statins

- PMLiVE

NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales

In England, more than six million people live with cardiovascular disease, costing the NHS around £7.4bn per year

AstraZeneca AZ

AstraZeneca’s Brilinta reduces rate of secondary stroke

Drug helps to prevent rate of stroke and death by 17%

- PMLiVE

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

- PMLiVE

Lundbeck gets US approval for migraine drug at heart of Alder takeover

US regulator clears CGRP inhibitor under Vyepti trade name

- PMLiVE

AZ says Brilinta hits the mark in new stroke trial

Drug met primary endpoint in phase 3 THALES trial

- PMLiVE

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline

- PMLiVE

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

- PMLiVE

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links